Innoviva’s Zoliflodacin: A Promising Antibiotic Driving Buy Rating Amidst Urgent Need for Drug-Resistant Infection Solutions
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating for Innoviva, setting a $45 target, due to promising Phase 3 trial results for zoliflodacin, an antibiotic for drug-resistant infections. The drug, effective against gonorrhea, has FDA's Qualified Infectious Disease Product designation, enhancing its market potential. Selvaraju sees high approval probability, making zoliflodacin a key value driver for Innoviva.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments